Technology
Health
Pharmaceutical

Y-mAbs

$21.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-0.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Y-mAbs and other stocks, options, ETFs, and crypto commission-free!

About

Y-mAbs Therapeutics, Inc. Common Stock, also called Y-mAbs, is a clinical-stage biopharmaceutical company. Read More It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Employees
32
Headquarters
New York, New York
Founded
2015
Market Cap
728.67M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
113.21K
High Today
$21.33
Low Today
$20.05
Open Price
$21.12
Volume
23.66K
52 Week High
$31.00
52 Week Low
$15.17

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
Engineering
2018 IPO

News

Yahoo FinanceMay 7

Here’s What Hedge Funds Think About Y-mAbs Therapeutics, Inc. (YMAB)

At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices.

17

Earnings

-$0.47
-$0.42
-$0.36
-$0.31
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.47 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.